A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Clinical trial NCT02573324 · COMPLETED

Trial details

NCT number: NCT02573324
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Glioblastoma Gliosarcoma

Start date: 2015-01-04
Primary completion: 2022-04-04
Enrollment: 691

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.